Combinatorial suicide gene strategies for the safety of cell therapies.
RQR8
inducible caspase 8
inducible caspase 9
safety switch
suicide gene
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
06
2022
accepted:
29
08
2022
entrez:
3
10
2022
pubmed:
4
10
2022
medline:
5
10
2022
Statut:
epublish
Résumé
Gene-modified cellular therapies carry inherent risks of severe and potentially fatal adverse events, including the expansion of alloreactive cells or malignant transformation due to insertional mutagenesis. Strategies to mitigate uncontrolled proliferation of gene-modified cells include co-transfection of a suicide gene, such as the inducible caspase 9 safety switch (ΔiC9). However, the activation of the ΔiC9 fails to completely eliminate all gene-modified cells. Therefore, we tested a two suicide gene system used independently or together, with the goal of complete cell elimination. The first approach combined the ΔiC9 with an inducible caspase 8, ΔiC8, which lacks the endogenous prodomain. The rationale was to use a second caspase with an alternative and complementary mechanism of action. Jurkat cells co-transduced to co-express the ΔiC8, activatable by a BB homodimerizer, and the ΔiC9 activatable by the rapamycin analog sirolimus were used in a model to estimate the degree of inducible cell elimination. We found that both agents could activate each caspase independently, with enhanced elimination with superior reduction in cell regrowth of gene-modified cells when both systems were activated simultaneously. A second approach was employed in parallel, combining the ΔiC9 with the RQR8 compact suicide gene. RQR8 incorporates a CD20 mimotope, targeted by the anti-CD20 monoclonal antibody rituxan, and the QBend10, a ΔCD34 selectable marker. Likewise, enhanced cell elimination with superior reduction in cell regrowth was observed when both systems were activated together. A dose-titration effect was also noted utilizing the BB homodimerizer, whereas sirolimus remained very potent at minimal concentrations. Further
Identifiants
pubmed: 36189285
doi: 10.3389/fimmu.2022.975233
pmc: PMC9515659
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Caspase 8
EC 3.4.22.-
Caspase 9
EC 3.4.22.-
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
975233Informations de copyright
Copyright © 2022 Falcon, Smith, Al-Obaidi, Abu Zaanona, Purvis, Minagawa, Athar, Salzman, Bhatia, Goldman and Di Stasi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Stem Cells. 2010 Jun;28(6):1107-15
pubmed: 20506146
J Immunol. 1991 Aug 15;147(4):1424-32
pubmed: 1714482
Blood. 2018 Jan 18;131(3):311-322
pubmed: 29122757
Mol Ther. 2010 Apr;18(4):843-51
pubmed: 20179677
Science. 1998 Nov 13;282(5392):1318-21
pubmed: 9812896
Blood. 2021 Jun 10;137(23):3306-3309
pubmed: 33624095
Biol Blood Marrow Transplant. 2007 Aug;13(8):913-24
pubmed: 17640595
N Engl J Med. 2011 Nov 3;365(18):1673-83
pubmed: 22047558
J Am Soc Nephrol. 2010 Jul;21(7):1218-22
pubmed: 20558536
Mol Ther. 2016 Apr;24(4):823-31
pubmed: 26708005
PLoS Med. 2009 Feb 17;6(2):e1000029
pubmed: 19226183
J Clin Invest. 2008 Sep;118(9):3132-42
pubmed: 18688285
Cancer J. 2014 Mar-Apr;20(2):127-33
pubmed: 24667958
Biomedicines. 2017 Jun 14;5(2):
pubmed: 28613269
Nat Med. 2006 Apr;12(4):401-9
pubmed: 16582916
Stem Cells. 2015 Jan;33(1):91-100
pubmed: 25330775
Stem Cell Reports. 2015 Oct 13;5(4):597-608
pubmed: 26321144
Mol Ther Nucleic Acids. 2013 Sep 17;2:e122
pubmed: 24045711
Mol Ther. 2011 Sep;19(9):1667-75
pubmed: 21587213
Mol Ther. 2016 Apr;24(4):736-45
pubmed: 26639404
Mol Ther. 2018 May 2;26(5):1266-1276
pubmed: 29661681
Biomaterials. 2012 Apr;33(11):3195-204
pubmed: 22269649
Blood. 2006 Sep 15;108(6):1797-808
pubmed: 16741253
Br J Haematol. 2000 Dec;111(4):1130-7
pubmed: 11167752
Blood. 2005 Jun 1;105(11):4247-54
pubmed: 15728125
Nat Biotechnol. 2020 Dec;38(12):1441-1450
pubmed: 32661439
Genesis. 2007 Apr;45(4):194-9
pubmed: 17417788
Blood. 2015 Jun 25;125(26):4103-13
pubmed: 25977584
Sci Transl Med. 2014 Mar 12;6(227):227ra33
pubmed: 24622513
Anticancer Res. 2009 Nov;29(11):4717-26
pubmed: 20032425
Nat Commun. 2020 Jun 1;11(1):2713
pubmed: 32483127
Nature. 2010 Sep 16;467(7313):318-22
pubmed: 20844535
Semin Immunol. 1998 Aug;10(4):267-77
pubmed: 9695183
PLoS One. 2016 Dec 1;11(12):e0166891
pubmed: 27907031
Chem Biol. 1996 Sep;3(9):731-8
pubmed: 8939689
J Gen Virol. 2001 May;82(Pt 5):1013-1025
pubmed: 11297676
J Biol Chem. 2010 May 28;285(22):16632-42
pubmed: 20308068
Curr Biol. 1996 Jul 1;6(7):839-47
pubmed: 8805308
N Engl J Med. 2017 Mar 16;376(11):1007-1009
pubmed: 27959704
Blood. 2013 Aug 22;122(8):1341-9
pubmed: 23741009
Cancer Discov. 2020 May;10(5):702-723
pubmed: 32193224
Blood. 2009 Jun 18;113(25):6392-402
pubmed: 19377047
Blood. 2012 Jun 14;119(24):5697-705
pubmed: 22535661
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3655-60
pubmed: 9520421
Int J Mol Med. 2018 Oct;42(4):1977-1986
pubmed: 30085335
J Gen Virol. 2001 May;82(Pt 5):1027-1041
pubmed: 11297677
Cold Spring Harb Perspect Biol. 2013 Mar 01;5(3):a008904
pubmed: 23457258
N Engl J Med. 2010 Jul 22;363(4):355-64
pubmed: 20660403
N Engl J Med. 2010 Nov 11;363(20):1918-27
pubmed: 21067383
Blood. 2014 Aug 21;124(8):1277-87
pubmed: 24970931
Cancer Gene Ther. 2014 Nov;21(11):472-482
pubmed: 25323693